<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HPF - Moria - Alchimia</title>
	<atom:link href="https://alchimiasrl.com/information/ophthalmic-surgery/perfluorocarbons/hpf/feed/" rel="self" type="application/rss+xml" />
	<link>https://alchimiasrl.com/information/ophthalmic-surgery/perfluorocarbons/hpf/</link>
	<description>Your ideas, our solutions</description>
	<lastBuildDate>Thu, 29 Dec 2022 16:58:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://alchimiasrl.com/wp-content/uploads/2020/03/cropped-Icon-per-sito-32x32.jpg</url>
	<title>HPF - Moria - Alchimia</title>
	<link>https://alchimiasrl.com/information/ophthalmic-surgery/perfluorocarbons/hpf/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</title>
		<link>https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 29 Dec 2022 16:58:45 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22744</guid>

					<description><![CDATA[<p>Year: 2022 Authors: Gatto C.; Ruzza P.; Giurgola L.; Honisch C.; Rossi O.; Romano M. R.; Ragazzi E.; D'Amato Tóthová J.     ACS Omega Journal doi/10.1021/acsomega.2c04697 Online version This is a: Publication   The purpose of this study is to compare the in vitro cytotoxicity tests according to the ISO  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/">Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-1"><p><strong>Year:</strong> 2022</p>
<p><strong>Authors</strong>: <span class="hlFld-ContribAuthor">Gatto C.; </span><span class="hlFld-ContribAuthor">Ruzza P.; </span><span class="hlFld-ContribAuthor">Giurgola L.; </span><span class="hlFld-ContribAuthor">Honisch C.; </span><span class="hlFld-ContribAuthor">Rossi O.; </span><span class="hlFld-ContribAuthor">Romano M. R.; </span><span class="hlFld-ContribAuthor">Ragazzi E.; D&#8217;Amato Tóthová J.</span></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-2"><p><span class="journal-name">ACS Omega Journal</span><br />
doi/10.1021/acsomega.2c04697<br />
<a href="https://pubs.acs.org/doi/10.1021/acsomega.2c04697">Online version</a></p>
</div><div class="fusion-text fusion-text-3"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-4"><p id="Abstract" class="article_abstract-title"><span style="font-size: 16px;">The purpose of this study is to compare the in vitro cytotoxicity tests according to the ISO 10993-5 (2009) standards using direct contact and the test on liquid extracts of compounds previously identified as possible toxic impurities in perfluorocarbon liquids (PFCLs) for use in vitreoretinal surgery. Compounds including perfluorooctanoic acid (PFOA), 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-perfluorooctane (1H-PFO), 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-tridecafluoro-2-methylpentane, 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-octafluorocyclopentane, and 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,3</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-decafluoropentane were analyzed by </span><sup>19</sup><span style="font-size: 16px;">F NMR before and after extraction using an aqueous solution and tested by both the direct contact and liquid extract tests in L929, BALB 3T3, and ARPE-12 cells. The concentration that reduced in vitro cell viability by 30%, the cytotoxicity concentration threshold (CC</span><sub>30</sub><span style="font-size: 16px;">), was determined for each compound. </span><sup>19</sup><span style="font-size: 16px;">F NMR spectroscopy confirmed the immiscibility of perfluoro-</span><i style="font-size: 16px;">n</i><span style="font-size: 16px;">-octane (PFO) and 1H-PFO and the solubility of PFOA with the extraction vehicle. The other samples reacted with the extraction vehicle, releasing fluoride ions. Using the direct contact test, the CC</span><sub>30</sub><span style="font-size: 16px;"> of PFOA, 1H-PFO, 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-tridecafluoro-2-methylpentane, 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-octafluorocyclopentane, and 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,3</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-decafluoropentane corresponded to 48 124, 50, 14, 8035, and 46 ppm, respectively. The method on liquid extracts did not detect cytotoxicity in three out of five tested compounds, and CC</span><sub>30</sub><span style="font-size: 16px;"> could not be determined. In conclusion, the in vitro cytotoxicity test by direct contact revealed a positive correlation between cell toxicity and the concentration of the tested substance. Conversely, the test on liquid extracts hardly detected the cytotoxicity of toxic impurities in PFCLs. Thus, only the cytotoxicity test by direct contact, according to ISO 10993-5 (2009), is a sensible and reliable method to detect possible cytotoxic impurities in PFCLs to guarantee patient safety.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/">Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Ex vivo evaluation of retinal cytotoxicity after the use of multiple medical devices in pars plana vitrectomy in porcine eyes</title>
		<link>https://alchimiasrl.com/ex-vivo-evaluation-of-retinal-cytotoxicity-after-the-use-of-multiple-medical-devices-in-pars-plana-vitrectomy-in-porcine-eyes/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Tue, 23 Nov 2021 16:56:28 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<category><![CDATA[RS-OIL]]></category>
		<category><![CDATA[Silicone oils]]></category>
		<category><![CDATA[Twin]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=21820</guid>

					<description><![CDATA[<p>Year: 2021 Authors: Gatto C.; Romano M.R.; Giurgola L.; Ferrara M.; Ragazzi E.; D'Amato Tóthová J.     Experimental Eye Research  10.1016/j.exer.2021.108837 Online version This is a: Publication   This study aimed to evaluate viability of retinal cells after the use of multiple intraoperative devices, namely a vitreal dye (triamcinolone acetonide,TA), a  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/ex-vivo-evaluation-of-retinal-cytotoxicity-after-the-use-of-multiple-medical-devices-in-pars-plana-vitrectomy-in-porcine-eyes/">Ex vivo evaluation of retinal cytotoxicity after the use of multiple medical devices in pars plana vitrectomy in porcine eyes</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-5"><p><strong>Year:</strong> 2021</p>
<p><strong>Authors</strong>: Gatto C.; Romano M.R.; Giurgola L.; Ferrara M.; Ragazzi E.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-6"><p><span class="journal-name">Experimental Eye Research </span><br />
10.1016/j.exer.2021.108837<br />
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0014483521004036?via%3Dihub">Online version</a></p>
</div><div class="fusion-text fusion-text-7"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-8"><div class="align-m">
<p>This study aimed to evaluate viability of retinal cells after the use of multiple intraoperative devices, namely a vitreal dye (triamcinolone acetonide,TA), a ERM/ILM dye (solution of trypan blue 0.15% and brilliant blue 0.025%), and two intraocular tamponades, namely perfluoro-n-octane, (PFO) and silicone oil (SO 1000 cSt), with minimal and maximal removal of their residues, during a simulated pars plana vitrectomy (PPV) in porcine eyes ex-vivo. The in vitro cytotoxicity of each of these compounds was verified on ARPE-19 cells by direct tests according to the ISO 10993-5 (2009). Pars plana vitrectomy was performed on 25 enucleated porcine eyes divided in five groups according to the following conditions: Group A) No surgery control: eye bulbs were kept at room temperature for 40 min; Group B) Sham surgery: PPV with the sole use of BSS for 40 min; Group C) Cytotoxic control: PPV with BSS infusion (20 min) followed by intravitreal injection of 1H-PFO (contact time: 20 min); Group D) Surgery with residues: PPV with BSS infusion and sequential intravitreal injection of TA, ERM/ILM dye, PFO and SO, with minimal removal of each compound after a specified contact-time (overall duration: 40 min); Group E) Surgery with minimal residues: PPV performed as in group D, but with maximal removal of each compound (overall duration: 40 min). All the experimental procedures were performed at room temperature.<br />
Immediately after surgery, the retina was extracted from each eye bulb and samples of 3-mm diameter were prepared. Retinal viability was determined for each sample by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay. A cell viability &lt;70% was considered the cytotoxicity threshold. Kruskal-Wallis test was used to evaluate the differences in retinal viability between groups. No cytotoxicity was detected in retinal samples in groups A, B and E. Samples from eye bulbs that had undergone surgery with minimal removal of residues (group D) and cytotoxic controls (group C) showed high retinal cytotoxicity. The tested conditions indicated that the combined use of TA, ERM/ILM dye, PFO and SO during PPV does not affect retinal cells viability if all the devices are properly removed, whereas the cytotoxicity detected in group D may suggest that the presence and accumulation of the residues of the compounds used intraoperatively could negatively impact retinal viability due to a cumulative and/or synergistic cytotoxic effect between them, supporting the crucial role of an optimal removal of the intraoperative medical devices to ensure a safe vitrectomy to the patient.</p>
</div>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/ex-vivo-evaluation-of-retinal-cytotoxicity-after-the-use-of-multiple-medical-devices-in-pars-plana-vitrectomy-in-porcine-eyes/">Ex vivo evaluation of retinal cytotoxicity after the use of multiple medical devices in pars plana vitrectomy in porcine eyes</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid</title>
		<link>https://alchimiasrl.com/intraocular-toxicity-caused-by-meroctane-perfluorocarbon-liquid/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Fri, 15 Jan 2021 15:49:43 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=20836</guid>

					<description><![CDATA[<p>Year: 2021 Authors: Coco-Martin R. M.; Andrés-Iglesias C.; Srivastava G. K.; Lagos-Rodriguez J.; Ruiz-Tevah M.; Díaz-Cárdenas M. R.; Fernandez-Bueno I.; García-Serna J.; García-Gutierrez M. T.; García-Layana A.; Pastor J. C.     Sci Rep 11, 599 (2021) doi.org/10.1038/s41598-020-79561-y Online version This is a: Publication   Abstract Serious intraocular toxicity cases have been reported worldwide after  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/intraocular-toxicity-caused-by-meroctane-perfluorocarbon-liquid/">Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-3 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-9"><p><strong>Year:</strong> 2021</p>
<p><strong>Authors</strong>: <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Rosa_M_-Coco_Martin" aria-pressed="false" aria-expanded="false">Coco-Martin R. M.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Cristina-Andr_s_Iglesias" data-corresp-id="c1" aria-pressed="false" aria-expanded="false">Andrés-Iglesias C.;</a> <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Girish_K_-Srivastava" aria-pressed="false" aria-expanded="false">Srivastava G. K.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Javier-Lagos_Rodriguez" aria-pressed="false" aria-expanded="false">Lagos-Rodriguez J.;</a> <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Miguel-Ruiz_Tevah" aria-pressed="false" aria-expanded="false">Ruiz-Tevah M.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Mario_R_-D_az_C_rdenas" aria-pressed="false" aria-expanded="false">Díaz-Cárdenas M. R.;</a> <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Ivan-Fernandez_Bueno" aria-pressed="false" aria-expanded="false">Fernandez-Bueno I.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Juan-Garc_a_Serna" aria-pressed="false" aria-expanded="false">García-Serna J.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Mar_a_T_-Garc_a_Gutierrez" aria-pressed="false" aria-expanded="false">García-Gutierrez M. T.;</a> <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Alfredo-Garc_a_Layana" aria-pressed="false" aria-expanded="false">García-Layana A.; </a><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-J__Carlos-Pastor" aria-pressed="false" aria-expanded="false">Pastor</a> J. C.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-10"><p>Sci Rep 11<b>, </b>599 (2021)<br />
doi.org/10.1038/s41598-020-79561-y<br />
<a href="https://www.nature.com/articles/s41598-020-79561-y">Online version</a></p>
</div><div class="fusion-text fusion-text-11"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-12"><p class="c-article__sub-heading" data-test="abstract-sub-heading"><strong>Abstract</strong><br />
Serious intraocular toxicity cases have been reported worldwide after the use of different perfluorocarbon liquids. The current study reports for the first-time the clinical pictures of cases of acute intraocular toxicity caused by MEROCTANE, a perfluoro-octane commercialized by a Turkish company and distributed in many countries. A series of 18 cases from Chile and Spain was retrospectively analysed. To evaluate the impurity profile, a suspicious MEROCTANE sample (lot OCT.01.2013) was analysed by gas chromatography mass spectrometry and compared with a non-suspicious sample of the same commercial perfluoro-octane (lot OCT 722011). Cytotoxicity was tested following a direct-contact method, taking into consideration the high volatility and hydrophobicity of perfluoro-octane and following the ISO 10993 guideline. Cytotoxicity test showed clear cytotoxic effects of the analysed batch (less than 9% of cell viability). Moreover, chemical analysis demonstrated the presence of many contaminants, some highly toxic (acids and alcohols). Perfluorocarbon liquids are useful tools for intraocular surgery but companies and Agencies of Medical Devices must implement measures that guarantee the safety of these products based on both chemical and cytotoxicity analysis for every batch<b>.</b> Medical staff should be encouraged to report any suspected case to their respective National Agencies.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/intraocular-toxicity-caused-by-meroctane-perfluorocarbon-liquid/">Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Evaluation of Cytotoxicity of Perfluorocarbons for Intraocular Use by Cytotoxicity Test In Vitro in Cell Lines</title>
		<link>https://alchimiasrl.com/evaluation-of-cytotoxicity-of-perfluorocarbons-for-intraocular-use-by-cytotoxicity-test-in-vitro-in-cell-lines/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Tue, 29 Oct 2019 12:05:02 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=18548</guid>

					<description><![CDATA[<p>Year: 2019 Authors: Romano R. M.; Ferrara M.; Gatto C.; Ferrari B.; Giurgola L.; D’Amato Tóthová J.     Translational Vision Science &amp; Technology: October 2019, Vol.8, 24 doi:10.1167/tvst.8.5.24 Online version This is a: Publication   Purpose: To validate the cytotoxicity test of perfluorocarbon liquids (PFCLs) for intraocular use according to the ISO  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/evaluation-of-cytotoxicity-of-perfluorocarbons-for-intraocular-use-by-cytotoxicity-test-in-vitro-in-cell-lines/">Evaluation of Cytotoxicity of Perfluorocarbons for Intraocular Use by Cytotoxicity Test In Vitro in Cell Lines</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-4 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-1 hover-type-none"><img fetchpriority="high" decoding="async" width="300" height="168" title="TVST logo" src="https://alchimiasrl.com/wp-content/uploads/2019/10/TVST-logo.png" alt class="img-responsive wp-image-18558" srcset="https://alchimiasrl.com/wp-content/uploads/2019/10/TVST-logo-200x112.png 200w, https://alchimiasrl.com/wp-content/uploads/2019/10/TVST-logo.png 300w" sizes="(max-width: 800px) 100vw, 300px" /></span></div></div><div class="fusion-text fusion-text-13"><p><strong>Year: </strong>2019</p>
<p><strong>Authors</strong>: <span class="hlFld-ContribAuthor">Romano R. M.; </span><span class="fontstyle0">Ferrara M.;</span><span class="fontstyle0"> Gatto C.; </span><span class="fontstyle0">Ferrari B.;</span><span class="fontstyle0"> Giurgola L.;</span><span class="fontstyle0"> <span class="hlFld-ContribAuthor">D’Amato Tóthová J.</span></span></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-14"><p><span class="journal-name">Translational Vision Science &amp; Technology</span>: October 2019, Vol.8, 24<br />
doi:10.1167/tvst.8.5.24<br />
<a href="https://tvst.arvojournals.org/article.aspx?articleid=2753104">Online version</a></p>
</div><div class="fusion-text fusion-text-15"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-16"><p><strong> <span class="fontstyle0">Purpose: </span></strong><span class="fontstyle2">To validate the cytotoxicity test of perfluorocarbon liquids (PFCLs) for intraocular use according to the ISO 10993-5 standard.<br />
</span></p>
<p><strong><span class="fontstyle0">Methods: </span></strong><span class="fontstyle2">BALB/3T3, ARPE-19 cell lines, and 3-mm human retina <em>ex vivo</em> samples were cultured in 96-well plates. Contact areas of 22%, 59%, and 83% and 2.5-, 12-, and 24-hour contact times were tested in cell lines. Cell viability was quantified by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in ARPE-19 and neutral red uptake (NRU) viability assay for BALB/3T3. Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay in ARPE-19 cells. 1-H perfluorooctane (1H PFO) and purified perfluorooctane (PFO) were used as cytotoxic and not cytotoxic controls, respectively. Cell viability was assessed by MTT assay in retina<em> ex vivo</em> samples.<br />
</span></p>
<p><span class="fontstyle0"><strong>Results:</strong> </span><span class="fontstyle2">Qualitative evaluation showed that cytotoxic control induced apoptosis, severe reactivity zones, and cytotoxicity according to ISO 10993-5 in all tested conditions. Quantitative evaluation of 1H PFO showed no cytotoxicity according to ISO 10993-5 on 22% areas, whereas cytotoxicity was detected on 59%, and 83% contact areas. The PFO was confirmed not to be cytotoxic in all tested conditions.<br />
</span><span class="fontstyle2">Quantitative evaluation in retina <em>ex vivo</em> samples confirmed no cytotoxicity with PFO and cytotoxicity with 1H PFO.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions: </span></strong><span class="fontstyle2">The direct contact cytotoxicity test according to ISO 10993-5 is a suitable method to detect the cytotoxicity of PFCLs and was validated using<br />
quantitative and qualitative approaches in ARPE-19 and BALB/3T3 cells covering 59% of the cell surface areas for 24 hours.<br />
</span></p>
<p><strong><span class="fontstyle0">Translational Relevance: </span></strong><span class="fontstyle2">Direct contact cytotoxicity test using specific conditions was validated, whereas different test conditions could not be validated.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/evaluation-of-cytotoxicity-of-perfluorocarbons-for-intraocular-use-by-cytotoxicity-test-in-vitro-in-cell-lines/">Evaluation of Cytotoxicity of Perfluorocarbons for Intraocular Use by Cytotoxicity Test In Vitro in Cell Lines</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>H content is not predictive of perfluorocarbon ocular endo-tamponades cytotoxicity in vitro</title>
		<link>https://alchimiasrl.com/h-content-is-not-predictive-of-perfluorocarbon-ocular-endo-tamponades-cytotoxicity-in-vitro/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 07 Aug 2019 07:40:53 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=17971</guid>

					<description><![CDATA[<p>Year: 2019 Authors: Ruzza P.; Gatto C.; Ragazzi E.; Romano R. M.; Honisch C.; D’Amato Tóthová J.     ACS Omega Journal: August 2, 2019 doi.org/10.1021/acsomega.9b01793 Online version This is a: Publication   Abstract: In recent years, cases of retinal toxicity occurred in some European, Middle Eastern, and South American countries following the use of perfluorocarbon liquids (PFCLs)  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/h-content-is-not-predictive-of-perfluorocarbon-ocular-endo-tamponades-cytotoxicity-in-vitro/">H content is not predictive of perfluorocarbon ocular endo-tamponades cytotoxicity in vitro</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-5 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-2 hover-type-none"><img decoding="async" width="200" height="200" title="ACS Omega 200" src="https://alchimiasrl.com/wp-content/uploads/2019/08/ACS-Omega-200.png" alt class="img-responsive wp-image-17973" srcset="https://alchimiasrl.com/wp-content/uploads/2019/08/ACS-Omega-200-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2019/08/ACS-Omega-200-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2019/08/ACS-Omega-200-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2019/08/ACS-Omega-200.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-17"><p><strong>Year: </strong>2019</p>
<p><strong>Authors</strong>: <span class="hlFld-ContribAuthor">Ruzza P.; </span><span class="hlFld-ContribAuthor">Gatto C.; </span><span class="hlFld-ContribAuthor">Ragazzi E.; </span><span class="hlFld-ContribAuthor">Romano R. M.; </span><span class="hlFld-ContribAuthor">Honisch C.; </span><span class="hlFld-ContribAuthor">D’Amato Tóthová J.</span></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-18"><p><span class="ej-keyword" data-value="Cornea">ACS Omega Journal</span>: <span id="ej-journal-date-volume-issue-pg">August 2, 2019</span><br />
doi.org/10.1021/acsomega.9b01793<br />
<a href="https://pubs.acs.org/doi/full/10.1021/acsomega.9b01793">Online version</a></p>
</div><div class="fusion-text fusion-text-19"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-20"><p><span class="abstract-section-header"><strong>Abstract:</strong> In recent years, cases of retinal toxicity occurred in some European, Middle Eastern, and South American countries following the use of perfluorocarbon liquids (PFCLs) on vitreoretinal surgeries owing to impurities in the product. Moreover, Spanish ophthalmologists reported several toxic cases on the use of perfluoro-<i>n</i>-octane Ala Octa (Alamedics, Dornstadt, Germany), raising the necessity of reviewing the current validated methods used for assessing the safety of PFCLs. We proved that in samples of PFCLs contaminated on purpose with impurities previously detected in Ala Octa devices, the determination of the so-called H-content using a <sup>1</sup>H NMR quantitative assay implemented with the electronic reference to access <em>in vivo</em> concentrations 2 technology failed to demonstrate a correlation between the H-content and in vitro cytotoxicity test in ARPE-19 and BALB 3T3 cell lines. Therefore, direct information on the safety of PFCLs was provided only by the cytotoxicity test in vitro validated according to ISO 10993-5, and the H-content was not predictive of perfluorocarbon ocular endotamponade cytotoxicity <em>in vitro</em>.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/h-content-is-not-predictive-of-perfluorocarbon-ocular-endo-tamponades-cytotoxicity-in-vitro/">H content is not predictive of perfluorocarbon ocular endo-tamponades cytotoxicity in vitro</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</title>
		<link>https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 16:46:29 +0000</pubDate>
				<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[HPF]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=13329</guid>

					<description><![CDATA[<p>Year: 2018, Euretina Authors: Romano M. Co-Authors: Gatto C.; Giurgola L.; Ferrara M.; D'Amato Tóthová J.   Methods: Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-6 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-3 hover-type-none"><img decoding="async" width="200" height="200" title="Euretina 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png" alt class="img-responsive wp-image-12355" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-21"><p><strong>Year:</strong> 2018, Euretina</p>
<p><strong>Authors</strong>: Romano M.</p>
<p><strong>Co-Authors</strong>: Gatto C.; Giurgola L.; Ferrara M.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-22"><p><strong> <span class="fontstyle0">Methods</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.<br />
</span></p>
<p><strong><span class="fontstyle0">Results</span></strong><span class="fontstyle0"><strong>:</strong> </span><span class="fontstyle0">Traces of paraxylene, ethylbenzene, and PFOA (≤30ppm) induced severe toxicity in both cell lines. Hexafluoro-1,2,3,4-tetrachlorobutane and H,1H,7H-Dodecafluoro-1-heptanol were cytotoxic at approximately 10000 ppm. 1H perfluorooctan was cytotoxic at approximately 60000 ppm. High concentrations of 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions</span></strong><span class="fontstyle0"><strong>:</strong> S</span><span class="fontstyle0">ix out of eight perfluorocarbon manufacturing process residuals showed cytotoxicity in the direct contact test according to ISO 10993-5. Paraxylene, ethylbenzene, and PFOA were the most cytotoxic compounds. 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</title>
		<link>https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 16:40:13 +0000</pubDate>
				<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[HPF]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=13325</guid>

					<description><![CDATA[<p>Year: 2018, Euretina Authors: Romano M. Co-Authors: Gatto C.; Giurgola L.; Ferrara M.; D'Amato Tóthová J.   Methods: BALB3T3 and ARPE19 cell lines were cultured in 96-well plates for direct contact cytotoxicity test of 22%, 59%, and 83% contact areas and 2.5, 12, and 24 h contact times. Cell morphology was graded by light microscopy. Cell  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/">Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-7 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-4 hover-type-none"><img decoding="async" width="200" height="200" title="Euretina 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png" alt class="img-responsive wp-image-12355" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-23"><p><strong>Year:</strong> 2018, Euretina</p>
<p><strong>Authors</strong>: Romano M.</p>
<p><strong>Co-Authors</strong>: Gatto C.; Giurgola L.; Ferrara M.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-24"><p><strong> <span class="fontstyle0">Methods</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">BALB3T3 and ARPE19 cell lines were cultured in 96-well plates for direct contact cytotoxicity test of 22%, 59%, and 83% contact areas and 2.5, 12, and 24 h contact times. Cell morphology was graded by light microscopy. Cell viability was quantified by MTT assay in ARPE19 cells and neutral red uptake viability assay for BALB3T3. 1-H perfluorooctane (1H PFO) and purified perfluoro-n-octane (PFO) were used as positive and negative controls, respectively.</span></p>
<p><strong><span class="fontstyle0">Results</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Qualitative evaluation showed that positive control induced the presence of severe reactivity zones, resulting in 2.2 to 3.0 grading score, and cytotoxicity according to ISO 10993-5 in all tested conditions. Quantitative evaluation of 1H PFO applied on 22%, 59%, and 83% contact areas corresponded to 14–26%, 84–96%, and 86–99% cell mortality ranges, respectively. No cytotoxicity according to ISO 10993-5 was detected in tested cell lines, when 1H PFO was applied on a 22% area at the tested time intervals. The negative control was not cytotoxic with both approaches in all tested conditions.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Direct contact cytotoxicity test according to ISO 10993-5 of PFCLs was validated quantitatively and qualitatively, using ARPE19 and BALB 3T3 cell lines and covering 59% of the cell surface areas for 24 h of contact time. Test conditions using a smaller contact area could not be validated.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/">Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</title>
		<link>https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 28 Jul 2016 15:29:41 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12744</guid>

					<description><![CDATA[<p>Year: 2016 Authors: Martínez-Castillo V. J.; García-Arumí J.; Boixadera A.     Ophthalmology 123(7): 1563-9, 2016 Online version  This is a: Publication   Purpose: To report the surgical results of primary pseudophakic  rhegmatogenous retinal detachment (RRD) with only inferior retinal breaks (IRBs) repaired by pars plana vitrectomy (PPV) alone and complete drainage  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/">Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-8 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-25"><p><strong>Year: </strong>2016</p>
<p><strong>Authors:</strong> Martínez-Castillo V. J.; García-Arumí J.; Boixadera A.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-26"><p>Ophthalmology 123(7): 1563-9, 2016<br />
<a href="http://www.ncbi.nlm.nih.gov/pubmed/27126928">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-27"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-15 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-28"><p><strong>Purpose:</strong> To report the surgical results of primary pseudophakic  rhegmatogenous retinal detachment (RRD) with only inferior retinal breaks (IRBs) repaired by pars plana vitrectomy (PPV) alone and complete drainage of subretinal fluid.</p>
<p><strong>Design:</strong> Prospective, interventional cohort study.</p>
<p><strong>Participants:</strong> A total of 147 consecutive pseudophakic eyes of 147 patients with primary RRD with causative inferior breaks.</p>
<p><strong>Methods:</strong> All eyes underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6), or 12% perfluoropropane (C3F8) as tamponade and with no face-down position in the postoperative period.</p>
<p><strong>Main Outcome Measures:</strong> Postoperative primary and final anatomic outcome, visual acuity, and complications.</p>
<p><strong>Results:</strong> The patient population consisted of 44 women (30%) and 103 men (70%) with a mean age of 60.812.9 years. The mean follow-up period was 24.919.4 months. The mean number of quadrants affected was 2.4 (range, 1e4). A single break was present in 90 cases (61.2%), and 2 to 4 breaks were present in 57 cases (38.8%). The macula was found to be detached in 118 cases (80.3%) and attached in 29 cases (19.7%) intraoperatively.<br />
Of 152 breaks located between 5 and 7 clock-hours, 124 breaks (81.6%) were located outside the limits of the gas bubble on the first or third day postoperatively. Initial reattachment was achieved in 139 cases (94.5%; 95% confidence interval, 89.5e97.6). Final reattachment was achieved in 147 cases (100%). Two cases (1.3%) redetached because of new or missed retinal breaks. Six cases (4.1%) redetached because of incomplete retinal adhesion of the treated break(s). Mean preoperative best-corrected visual acuity (BCVA) was 1.110.59 logarithm of the minimum angle of resolution (logMAR). The mean final postoperative BCVA was 0.420.33 logMAR.</p>
<p><strong>Conclusions:</strong> Pars plana vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in the management of primary pseudophakic RRD due to IRBs.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/">Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</title>
		<link>https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Sat, 28 Jul 2012 15:28:05 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12742</guid>

					<description><![CDATA[<p>Year: 2012  Authors: Romano M.R.; Vallejo-Garcia J.L.; Parmeggiani F.; Vito R.; Vinciguerra P.     Curr Eye Res. 37(7): 563-6, 2012 Online version  This is a: Publication   Abstract: Interactions between perfluoro-n-octane (PFO) or perfluorodecalin (PFD) and heavy silicone oil (HSO, either alkane or ether) were studied in vitro by incubating fluids  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/">Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-9 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-16 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-29"><p><strong>Year: </strong>2012<strong> </strong></p>
<p><strong>Authors</strong>: Romano M.R.; Vallejo-Garcia J.L.; Parmeggiani F.; Vito R.; Vinciguerra P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-30"><p>Curr Eye Res. 37(7): 563-6, 2012<br />
<a href="http://www.ncbi.nlm.nih.gov/pubmed/22578277">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-31"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-17 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-32"><p><strong>Abstract: </strong>Interactions between perfluoro-n-octane (PFO) or perfluorodecalin (PFD) and heavy silicone oil (HSO, either alkane or ether) were studied in vitro by incubating fluids for 7 days at regulated temperatures.</p>
<p>The samples were divided into two groups: Group A, PFCL (PFO or PFD) + 5 ml of HSO (silicone oil + alkane or ether); Group B, HSO (silicone oil + alkane or ether) without perfluorocarbons (PFCLs).</p>
<p>Each sample was kept at 36°C for 7 days. HSOs were then removed with a 20 G, 7 mm-long cannula under 600 mm Hg of vacuum pressure at two different temperatures: 36 and 22°C. The time needed to remove the oils and the presence of opacity was recorded. Each experiment was performed in triplicate. In vitro, interactions between PFCLs and HSO oil led to the formation of hyper-viscous solutions with significant increase in aspiration time in Group A. (P = 0.006, Kruskal–Wallis test). Temperature was also found to affect HSOs’ saturation, as a decrease in temperature determined an increase in opacity and shear viscosity of the solution (P = 0.02, Kruskal–Wallis test).</p>
<p>No differences between alkane and ether (P = 0.74) and perfluoro-n-octane and perfluorodecalin (P=0.56) was found. In conclusion, interactions between PFCL–HSO and variation in temperature lead to the formation of hyper-viscous solutions that could be described as “sticky oil”.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/">Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Ocular tolerance and efficacy of short-term tamponade with double filling of polydimethyloxane and perfluoro-n-octane</title>
		<link>https://alchimiasrl.com/ocular-tolerance-and-efficacy-of-short-term-tamponade-with-double-filling-of-polydimethyloxane-and-perfluoro-n-octane/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Sat, 28 May 2011 14:53:52 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<category><![CDATA[RS-OIL]]></category>
		<category><![CDATA[Silicone oils]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12715</guid>

					<description><![CDATA[<p>Year: 2011 Authors:  Zenoni S.; Romano M.R.; Palmieri S.; Comi N.; Fiorentini E.; Fontana P.     Clin Ophthalmol. 2011; 5: 443–449 Online version  This is a: Publication   Abstract: Double filling tamponade was performed in 30 eyes of 30 patients by 30% perfluoro-n-octane and 70% RS-OIL 1000 cS for an average  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/ocular-tolerance-and-efficacy-of-short-term-tamponade-with-double-filling-of-polydimethyloxane-and-perfluoro-n-octane/">Ocular tolerance and efficacy of short-term tamponade with double filling of polydimethyloxane and perfluoro-n-octane</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-10 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-18 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-33"><p><strong>Year:</strong> 2011</p>
<p><strong>Authors: </strong> Zenoni S.; Romano M.R.; Palmieri S.; Comi N.; Fiorentini E.; Fontana P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-34"><p>Clin Ophthalmol. 2011; 5: 443–449<br />
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090297/#!po=92.8571">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-35"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-19 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-36"><p><strong>Abstract: </strong>Double filling tamponade was performed in 30 eyes of 30 patients by 30% perfluoro-n-octane and 70% RS-OIL 1000 cS for an average of 23 days, after expanding the vitreous cavity with HPF10 perfluorodecalin.</p>
<p>The follow-up visits were scheduled 1 week, 1 month, and 3 months after surgery. The main outcome measures were visual acuity, intraocular pressure (IOP), PVR reproliferation, and electrophysiological parameters.</p>
<p>The primary success rate was 80% (24/30). Fourteen patients (46.7%) had a postoperative improvement in visual acuity, 12 patients (40.0%) maintained their preoperative visual acuity, and four patients (13.3%) experienced a reduction in visual acuity. In conclusion, our experience with double filling in selected cases of retinal detachment was positive.</p>
<p>No electroretinographic signs of retinal toxicity and a low incidence of PVR reproliferation were observed.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/ocular-tolerance-and-efficacy-of-short-term-tamponade-with-double-filling-of-polydimethyloxane-and-perfluoro-n-octane/">Ocular tolerance and efficacy of short-term tamponade with double filling of polydimethyloxane and perfluoro-n-octane</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
